Chemistry:Solitomab
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Mouse |
| Target | EpCAM |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Solitomab (INN; development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.[1][2][3]
Mechanism of action
Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between T cells and its target tumor cell antigen. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.[1][4] This action mimics physiological processes observed during T cell attacks against tumor cells.[4]
References
- ↑ 1.0 1.1 Helwick, Caroline (June 2008). "Novel BiTE antibody mediates contact between T cells and cancer cells". Oncology NEWS International 17 (6). http://www.cancernetwork.com/display/article/10165/1165525.
- ↑ Clinical trial number NCT00635596 for "Phase I Study of MT110 in Colorectal Cancer (CRC), Gastrointestinal (GI) and Lung Cancer (MT110-101)" at ClinicalTrials.gov
- ↑ "Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release". Journal of Immunotherapy 32 (5): 452–64. June 2009. doi:10.1097/CJI.0b013e3181a1c097. PMID 19609237.
- ↑ 4.0 4.1 "BiTE Antibody Platform". Micromet Inc. http://www.micromet.de/index.php?id=67.
 |  |
